Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin.

A. R. Thierry, T. J. Jorgensen, D. Forst, J. A. Belli, A. Dritschilo, A. Rahman

Research output: Contribution to journalArticle

Abstract

A Chinese hamster cell line (LZ), selected for multidrug resistance (MDR), exhibits a 3,000-fold resistance to doxorubicin, compared to parental V-79 cells. These drug resistant cells have amplified MDR genes, overexpress P-glycoprotein, and in the presence of doxorubicin show reduced intracellular drug accumulation. Using liposome-encapsulated doxorubicin (Rahman et al. Cancer Res. 45:796-803; 1985), we observed partial reversal of the resistance of LZ cells to this drug and a higher intracellular drug accumulation, compared to free drug. Parental V-79 cells, however, did not exhibit differences in survival or in drug accumulation when treated with encapsulated or free doxorubicin. Comparison of the effect of liposome-encapsulated doxorubicin with that of verapamil in reversing drug resistance showed that the liposomal preparation was as effective as verapamil used at its maximum clinically relevant concentration (1.5 microM). These results suggest that the use of liposomes as carriers of anticancer drugs may offer a strategy for overcoming MDR in tumor cells.

Original languageEnglish (US)
Pages (from-to)311-316
Number of pages6
JournalCancer Communications
Volume1
Issue number5
StatePublished - 1989
Externally publishedYes

Fingerprint

Multiple Drug Resistance
Cricetulus
Liposomes
Doxorubicin
Pharmaceutical Preparations
Verapamil
MDR Genes
Drug Carriers
P-Glycoprotein
Drug Resistance
Neoplasms
Cell Line

ASJC Scopus subject areas

  • Cancer Research

Cite this

Thierry, A. R., Jorgensen, T. J., Forst, D., Belli, J. A., Dritschilo, A., & Rahman, A. (1989). Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Communications, 1(5), 311-316.

Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. / Thierry, A. R.; Jorgensen, T. J.; Forst, D.; Belli, J. A.; Dritschilo, A.; Rahman, A.

In: Cancer Communications, Vol. 1, No. 5, 1989, p. 311-316.

Research output: Contribution to journalArticle

Thierry, AR, Jorgensen, TJ, Forst, D, Belli, JA, Dritschilo, A & Rahman, A 1989, 'Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin.', Cancer Communications, vol. 1, no. 5, pp. 311-316.
Thierry AR, Jorgensen TJ, Forst D, Belli JA, Dritschilo A, Rahman A. Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Communications. 1989;1(5):311-316.
Thierry, A. R. ; Jorgensen, T. J. ; Forst, D. ; Belli, J. A. ; Dritschilo, A. ; Rahman, A. / Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. In: Cancer Communications. 1989 ; Vol. 1, No. 5. pp. 311-316.
@article{e383c63b00ed4f22ba945fa28d16886c,
title = "Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin.",
abstract = "A Chinese hamster cell line (LZ), selected for multidrug resistance (MDR), exhibits a 3,000-fold resistance to doxorubicin, compared to parental V-79 cells. These drug resistant cells have amplified MDR genes, overexpress P-glycoprotein, and in the presence of doxorubicin show reduced intracellular drug accumulation. Using liposome-encapsulated doxorubicin (Rahman et al. Cancer Res. 45:796-803; 1985), we observed partial reversal of the resistance of LZ cells to this drug and a higher intracellular drug accumulation, compared to free drug. Parental V-79 cells, however, did not exhibit differences in survival or in drug accumulation when treated with encapsulated or free doxorubicin. Comparison of the effect of liposome-encapsulated doxorubicin with that of verapamil in reversing drug resistance showed that the liposomal preparation was as effective as verapamil used at its maximum clinically relevant concentration (1.5 microM). These results suggest that the use of liposomes as carriers of anticancer drugs may offer a strategy for overcoming MDR in tumor cells.",
author = "Thierry, {A. R.} and Jorgensen, {T. J.} and D. Forst and Belli, {J. A.} and A. Dritschilo and A. Rahman",
year = "1989",
language = "English (US)",
volume = "1",
pages = "311--316",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "5",

}

TY - JOUR

T1 - Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin.

AU - Thierry, A. R.

AU - Jorgensen, T. J.

AU - Forst, D.

AU - Belli, J. A.

AU - Dritschilo, A.

AU - Rahman, A.

PY - 1989

Y1 - 1989

N2 - A Chinese hamster cell line (LZ), selected for multidrug resistance (MDR), exhibits a 3,000-fold resistance to doxorubicin, compared to parental V-79 cells. These drug resistant cells have amplified MDR genes, overexpress P-glycoprotein, and in the presence of doxorubicin show reduced intracellular drug accumulation. Using liposome-encapsulated doxorubicin (Rahman et al. Cancer Res. 45:796-803; 1985), we observed partial reversal of the resistance of LZ cells to this drug and a higher intracellular drug accumulation, compared to free drug. Parental V-79 cells, however, did not exhibit differences in survival or in drug accumulation when treated with encapsulated or free doxorubicin. Comparison of the effect of liposome-encapsulated doxorubicin with that of verapamil in reversing drug resistance showed that the liposomal preparation was as effective as verapamil used at its maximum clinically relevant concentration (1.5 microM). These results suggest that the use of liposomes as carriers of anticancer drugs may offer a strategy for overcoming MDR in tumor cells.

AB - A Chinese hamster cell line (LZ), selected for multidrug resistance (MDR), exhibits a 3,000-fold resistance to doxorubicin, compared to parental V-79 cells. These drug resistant cells have amplified MDR genes, overexpress P-glycoprotein, and in the presence of doxorubicin show reduced intracellular drug accumulation. Using liposome-encapsulated doxorubicin (Rahman et al. Cancer Res. 45:796-803; 1985), we observed partial reversal of the resistance of LZ cells to this drug and a higher intracellular drug accumulation, compared to free drug. Parental V-79 cells, however, did not exhibit differences in survival or in drug accumulation when treated with encapsulated or free doxorubicin. Comparison of the effect of liposome-encapsulated doxorubicin with that of verapamil in reversing drug resistance showed that the liposomal preparation was as effective as verapamil used at its maximum clinically relevant concentration (1.5 microM). These results suggest that the use of liposomes as carriers of anticancer drugs may offer a strategy for overcoming MDR in tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=0024794421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024794421&partnerID=8YFLogxK

M3 - Article

C2 - 2577154

AN - SCOPUS:0024794421

VL - 1

SP - 311

EP - 316

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 5

ER -